JP7820821B2 - アルツハイマー病の治療のための化合物及び方法 - Google Patents
アルツハイマー病の治療のための化合物及び方法Info
- Publication number
- JP7820821B2 JP7820821B2 JP2022541987A JP2022541987A JP7820821B2 JP 7820821 B2 JP7820821 B2 JP 7820821B2 JP 2022541987 A JP2022541987 A JP 2022541987A JP 2022541987 A JP2022541987 A JP 2022541987A JP 7820821 B2 JP7820821 B2 JP 7820821B2
- Authority
- JP
- Japan
- Prior art keywords
- brichos
- amino acid
- bri2
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20150738.1 | 2020-01-08 | ||
| EP20150738 | 2020-01-08 | ||
| PCT/EP2021/050168 WO2021140140A1 (en) | 2020-01-08 | 2021-01-07 | Compound and method for treatment of alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509187A JP2023509187A (ja) | 2023-03-07 |
| JP2023509187A5 JP2023509187A5 (cg-RX-API-DMAC7.html) | 2024-01-30 |
| JP7820821B2 true JP7820821B2 (ja) | 2026-02-26 |
Family
ID=69156193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541987A Active JP7820821B2 (ja) | 2020-01-08 | 2021-01-07 | アルツハイマー病の治療のための化合物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12686706B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087860B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7820821B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115943153A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021140140A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120569207A (zh) | 2022-10-12 | 2025-08-29 | 阿尔法贝塔公司 | 将蛋白质递送到CNS神经元中的Bri2 BRICHOS结构域 |
| WO2025078660A1 (en) | 2023-10-11 | 2025-04-17 | Alphabeta Ab | The bri2 brichos domain for treatment of parkinson´s disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013533240A (ja) | 2010-06-24 | 2013-08-22 | アルファベータ・エービー | アルツハイマー病および家族性認知症の治療のための化合物および方法 |
| JP2014516407A (ja) | 2011-04-05 | 2014-07-10 | アルファベータ・エービー | 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1286697A (zh) * | 1998-12-10 | 2001-03-07 | 上海第二医科大学 | Npcahh01:人跨膜蛋白e3-16基因 |
| US20100098682A1 (en) * | 2005-06-14 | 2010-04-22 | D Adamio Luciano | Effect of Bri Proteins on Ass Production |
-
2021
- 2021-01-07 CN CN202180008401.XA patent/CN115943153A/zh active Pending
- 2021-01-07 US US17/784,591 patent/US12686706B2/en active Active
- 2021-01-07 EP EP21700377.1A patent/EP4087860B1/en active Active
- 2021-01-07 WO PCT/EP2021/050168 patent/WO2021140140A1/en not_active Ceased
- 2021-01-07 JP JP2022541987A patent/JP7820821B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013533240A (ja) | 2010-06-24 | 2013-08-22 | アルファベータ・エービー | アルツハイマー病および家族性認知症の治療のための化合物および方法 |
| JP2014516407A (ja) | 2011-04-05 | 2014-07-10 | アルファベータ・エービー | 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット |
Non-Patent Citations (2)
| Title |
|---|
| Sanchez-Pulido L et. al.,BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer,Trends Biochem Sci,2002年,27(7),pp. 329-32 |
| Willander H et. al.,BRICHOS domains efficiently delay fibrillation of amyloid β-peptide,J Biol Chem,2012年,287(37),pp. 31608-17 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115943153A (zh) | 2023-04-07 |
| EP4087860B1 (en) | 2023-11-22 |
| EP4087860C0 (en) | 2023-11-22 |
| US20230002458A1 (en) | 2023-01-05 |
| EP4087860A1 (en) | 2022-11-16 |
| JP2023509187A (ja) | 2023-03-07 |
| WO2021140140A1 (en) | 2021-07-15 |
| US12686706B2 (en) | 2026-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duan et al. | Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer’s disease | |
| Souchet et al. | Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice | |
| US9862761B2 (en) | Composition and method for preventing or treating a tauopathy | |
| Liu et al. | Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology | |
| CN101611152A (zh) | 用于调控set的方法及其用途 | |
| Cai et al. | Chronic cerebral hypoperfusion promotes amyloid-beta pathogenesis via activating β/γ-secretases | |
| KR20200095485A (ko) | 보체 활성의 조절인자 | |
| JP5893614B2 (ja) | アルツハイマー病および家族性認知症の治療のための化合物および方法 | |
| Lin et al. | Ozone inhibits APP/Aβ production and improves cognition in an APP/PS1 transgenic mouse model | |
| CN104321337A (zh) | 肽及其用途 | |
| Mishan et al. | Pathogenic tau protein species: Promising therapeutic targets for ocular neurodegenerative diseases | |
| US20250017884A1 (en) | Compositions and methods for treating alzheimer's disease | |
| EP4087860B1 (en) | Compound and method for treatment of alzheimer's disease | |
| Liu et al. | Role of mitochondrial quality control in neurodegenerative disease progression | |
| Gao et al. | Targeting the RAGE–RIPK1 binding site attenuates diabetes-associated cognitive deficits | |
| GB2571978A (en) | Uses, compositions and methods | |
| Morrissey et al. | The tripeptide RER mimics secreted amyloid precursor protein-alpha in upregulating LTP | |
| Zhang et al. | Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices | |
| Liu et al. | Biological effects and mechanism of β-amyloid aggregation inhibition by penetrable recombinant human HspB5-ACD structural domain protein | |
| Lee et al. | HDAC6 regulates BACE1 stability and NLRP3 inflammasome activation in Alzheimer’s disease | |
| KR20180133865A (ko) | 혈전성 혈소판감소성 자반 치료 약물 제조에 사용하는 항혈소판 트롬볼리신의 응용 | |
| Su et al. | TNMD BRICHOS domain attenuates tau pathology and memory deficits in a mouse model of tauopathy | |
| Noble et al. | Neurodegeneration Editors' Pick 2021 | |
| Habib | Therapeutic Modulation of Alzheimer's Disease with Biological (HUCBS) and Pharmacological (LISPRO) Approaches | |
| Hintermayer | The Role of the Tau N-Terminal Phosphatase-Activating Domain and Phosphorylation at Thr175 in the Formation of Tau Cytoplasmic Inclusions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240105 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240105 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7820821 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |